An Efficacy and Safety Study of Injectable Ravagalimab to Assess Change in EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI) in Adult Participants With Moderately to Severely Active Primary Sjogren's Syndrome (pSS)
Clinical trial NCT05217472 · WITHDRAWN
Trial details
- NCT number
- NCT05217472
- Sponsor
- AbbVie
- Status
- WITHDRAWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-03-06
- Primary completion
- 2022-04-15
- Enrollment
- 0
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.